Cargando…

Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States

INTRODUCTION: In 2012, the Advisory Committee on Immunization Practices (ACIP) revised recommendations for adult pneumococcal vaccination to include a sequential regimen of 13-valent pneumococcal conjugate vaccine (PCV13) followed by 23-valent pneumococcal polysaccharide vaccine (PPSV23) for certain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jieling, O’Brien, Megan A., Yang, H. Keri, Grabenstein, John D., Dasbach, Erik J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003344/ https://www.ncbi.nlm.nih.gov/pubmed/24718851 http://dx.doi.org/10.1007/s12325-014-0115-y

Ejemplares similares

1097 Cost-Effectiveness of Pneumococcal Vaccines for Adults in the United States
por: Yang, H. Keri, et al.
Publicado: (2014)

1094 Pneumococcal Vaccination Coverage In The Elderly In The United States: Missed Opportunities Continue
por: Yang, H. Keri, et al.
Publicado: (2014)

1101 The Gap Widens: Invasive Pneumococcal Serotype Distribution among Adults
por: Grabenstein, John D., et al.
Publicado: (2014)

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
por: Mangen, Marie-Josée J., et al.
Publicado: (2015)

06. United States Healthcare Provider Preferences for Adult Pneumococcal Vaccine Recommendations
por: Vietri, Jeffrey, et al.
Publicado: (2021)

647 Impact of 13-valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in the United States
por: Kim, Lindsay, et al.
Publicado: (2014)

Disparities in uptake of 13-valent pneumococcal conjugate vaccine among older adults in the United States
por: McLaughlin, John M., et al.
Publicado: (2019)

Vaccine Coverage for United States Infants at Milestone Ages: Missed Opportunities for Vaccination
por: Gebremeskel, Berhanu G., et al.
Publicado: (2016)

Preferences for Adult Pneumococcal Vaccine Recommendations Among United States Health Care Providers
por: Sacco, Patricia, et al.
Publicado: (2019)

Vaccine Escape Recombinants Emerge after Pneumococcal Vaccination in the United States
por: Brueggemann, Angela B, et al.
Publicado: (2007)

180. Impact of Pneumococcal Conjugative Vaccine on Antibiotic Resistant Invasive Pneumococcal Disease in the United States
por: Bajema, Kristina, et al.
Publicado: (2020)

Dosing Schedules for Pneumococcal Conjugate Vaccine: Considerations for Policy Makers
por: Whitney, Cynthia G., et al.
Publicado: (2014)

Potential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in Germany
por: Kuhlmann, Alexander, et al.
Publicado: (2012)

1373. Vaccine Effectiveness and Pneumococcal Serotypes in Pediatric Otitis Media in the Era of Routine 13-valent Pneumococcal Vaccination in the United States
por: Hulten, Kristina G, et al.
Publicado: (2020)

1068 Vaccine Coverage at Milestone Ages among Infants in the United States, 2009-2012
por: Gebremeskel, Berhanu, et al.
Publicado: (2014)

1439. The Cost-Effectiveness of Vaccinating Adults at Increased Risk of Pneumococcal Disease Against Pneumococcal Disease in The Netherlands
por: Rozenbaum, Mark
Publicado: (2018)

Cost of managing an episode of relapse in multiple sclerosis in the United States
por: O'Brien, Judith A, et al.
Publicado: (2003)

Vaccine humanity
por: Grabenstein, John D.
Publicado: (2022)

1740. Healthcare Providers’ Preferences for Pediatric Pneumococcal Vaccination Recommendations in the United States
por: Vietri, Jeffrey T, et al.
Publicado: (2023)

Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
por: Ordóñez, Jaime E, et al.
Publicado: (2014)

Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey
por: Sevilla, J. P., et al.
Publicado: (2020)

Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
por: Polistena, Barbara, et al.
Publicado: (2022)

Systematic Review of the Indirect Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Pneumococcal Disease and Colonization
por: Loo, Jennifer D., et al.
Publicado: (2014)

Disparities in Uptake of 13-valent Pneumococcal Conjugate Vaccine among Older Adults Following Routine Recommendation in the United States
por: McLaughlin, John, et al.
Publicado: (2017)

The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults
por: Feldman, Charles, et al.
Publicado: (2020)

Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States
por: Senders, Shelly, et al.
Publicado: (2021)

Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Vaccine-type Invasive Pneumococcal Disease Among Young Children
por: Conklin, Laura, et al.
Publicado: (2014)

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
por: Kobayashi, Miwako, et al.
Publicado: (2022)

The Serotype Distribution among Healthy Carriers before Vaccination Is Essential for Predicting the Impact of Pneumococcal Conjugate Vaccine on Invasive Disease
por: Flasche, Stefan, et al.
Publicado: (2015)

Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany
por: Kuchenbecker, Ulrike, et al.
Publicado: (2018)

Effectiveness of pneumococcal and influenza vaccines to prevent serious health complications in adults with chronic liver disease: a protocol for a systematic review
por: Härmälä, Suvi, et al.
Publicado: (2018)

Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
por: Asai, Nobuhiro, et al.
Publicado: (2021)

Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine
por: Baxter, Roger, et al.
Publicado: (2015)

Why Do We Need a Systematic Review of Pneumococcal Conjugate Vaccine Dosing Schedules?
por: O’Brien, Katherine L., et al.
Publicado: (2014)

Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023
por: Kobayashi, Miwako, et al.
Publicado: (2023)

Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom
por: Wilson, Michele, et al.
Publicado: (2023)

1474. Impact of 13-valent Pneumococcal Conjugate Vaccine (PCV13) on Non-bacteremic Pneumococcal Pneumonia (NBPP) among Adults in the United States, 2013-2017
por: Gierke, Ryan, et al.
Publicado: (2020)

Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
por: Malene B, Mikkelsen, et al.
Publicado: (2023)

A cost-effectiveness analysis of the 13-valent pneumococcal conjugated vaccine and the 23-valent pneumococcal polysaccharide vaccine among Thai older adult
por: Ngamprasertchai, Thundon, et al.
Publicado: (2023)

Model for Assessing Human Papillomavirus Vaccination Strategies
por: Elbasha, Elamin H., et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_bt4obikfftdo7bjvgnap3deei7